If a Coronary Bypass Fails in the Heart Can It Be Done Again?

Coronary bypass graft surgery is a landmark date in the lives of people who need it, marking the transition to significantly improved quality (and frequently quantity) of life (Figure). Evolution of bypass graft failure is some other landmark date that frequently signals the beginning of the end. As reported by Iqbal et al¹ in this issue of Circulation: Cardiovascular Interventions, bloodshed during the offset twelvemonth after bypass graft failure is loftier (v%–9%), well above the 3% threshold, used to define loftier cardiac risk.

• Download effigy
• Download PowerPoint

Effigy. Overview of various treatments during the entire lifespan of patients who undergo coronary bypass graft surgery (CABG). DES indicates drug-eluting stent; EPD, embolic protection device; GP IIb/IIIa, glycoprotein IIb/IIIa inhibitors; PCI, percutaneous coronary intervention; PCSK9i, proprotein convertase subtilisin/kexin blazon 9 (PCSK-9) inhibitors; P₂Y₁₂i, P₂Y₁₂ platelet receptor antagonists; and SVG, saphenous vein graft.

See Article by Iqbal et al

Can the loftier chance of death (and nonfatal events, such as myocardial infarction and repeat revascularization) be modified? Performing meticulous revascularization of the culprit lesion could minimize the take a chance of acute and chronic complications originating from that lesion. Still, subsequent adverse events can also be caused by coronary artery disease progression at different locations of the culprit graft, at different bypass grafts, or in the native coronary circulation. Patients may besides develop noncoronary cardiac diseases, such as progressive heart failure and arrhythmias, or noncardiac diseases, such equally cancer or infection (Effigy), which cannot be modified past treating the culprit featherbed graft lesion or by administering atherosclerosis treatments.

When a patient presents with bypass graft failure, we primarily focus on providing acute symptom relief and minimizing the risk that the culprit graft (or other bypass grafts or native coronary arteries) fails again.^two Bypass graft percutaneous coronary intervention (PCI) of the culprit lesion (which is usually located in a saphenous vein graft [SVG]^3,4) is performed, ideally using an embolic protection device.^v Bare metallic stents (BMS) improved outcomes of SVG PCI when compared with balloon angioplasty, merely had loftier run a risk for restenosis.² Drug-eluting stents (DES) reduced restenosis and cardiac events when compared with BMS in three of the 4 published or presented clinical SVG PCI trials to engagement and are currently the handling of choice for SVG lesions⁶; although given the paucity of randomized data, their efficacy and safe in this setting remains uncertain.

Iqbal et al¹ present a large analysis of outcomes after featherbed graft stenting equally a function of stent type used in 15 003 patients treated in England and Wales betwixt 2006 and 2013. One-year bloodshed was high (v% to nine%), apply of DES increased over time to ≈80% in 2013, and patients who received BMS had higher bloodshed than those who received DES. Afterward adjustment, the clan of BMS with higher mortality remained statistically significant when compared with second-generation DES, only not when compared with first-generation DES (probable because of lower power, given the smaller number of patients who received showtime-generation DES).

Practice, therefore, second-generation DES reduce mortality in patients presenting with bypass graft failure? This report does non and cannot answer this question. No registry study, no matter how large or how well adjusted, can account for measured and unmeasured differences betwixt the groups studied. Patients who received BMS were conspicuously at higher risk than those who received DES (older historic period, lower ejection fraction, more likely to be in cardiogenic shock, more than likely to receive an intra-aortic balloon pump, possibly receiving longer elapsing of dual antiplatelet therapy). The decision to use a BMS was probable influenced to a large extent from this higher baseline run a risk. In-infirmary mortality was higher in the BMS group (iii% for BMS versus ane% in the DES group, or 2% absolute deviation), which besides explains most of the mortality difference at 1 year (9% in the BMS group versus 5% in the first-generation DES group versus 6% in the second-generation DES group,^ane or three%–4% absolute difference).

DES (beginning or second generation) are unlikely to lower bloodshed in patients presenting with bypass graft failure for multiple reasons. First, DES reduce restenosis of the target SVG or arterial graft but do not affect other parts of the aforementioned graft or other grafts. Intermediate SVG lesions (in the same or other grafts) ofttimes progress to severe,^seven and prophylactic stenting of such lesions (at least with kickoff-generation DES) has not been benign.^viii 2nd, such patients are at increased risk for disease progression in the native coronary circulation that may or may non be amenable to revascularization.^iii,4 Third, patients presenting with bypass graft failure are oftentimes sometime (hateful age was 68–seventy years in this study) and have worse baseline left ventricular function, hence may be at increased risk for eye failure or arrhythmias, and for developing noncardiac illness, such as infections and cancer. Before registry studies of BMS versus DES showed lower mortality with DES, whereas randomized studies showed like mortality.^nine A more definitive respond on how PCI with 2nd-generation DES compares with BMS in SVGs will be provided by the DIVA multicenter VA cooperative trial (Drug-Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Angioplasty [NCT01121224]), that was designed to accost the limitations of previous randomized trials, that is, small sample size, routine angiographic follow-up, lack of blinding, low utilise of embolic protection devices, and apply of first-generation DES. Enrollment and follow-upward of 599 patients has been completed, and results will be available later in 2017.

Iqbal et al¹ provide some additional insights on the contemporary treatment of featherbed graft failure. Although radial artery is the predominant admission site in the Britain, it was but used in 17% to 35% of bypass graft PCI cases, highlighting the advantages of femoral access in this setting.¹⁰ Glycoprotein IIb/IIIa inhibitors were used in a 20% to 32% of patients, despite prove that they do non provide benefit and may actually cause harm.¹¹ Conversely, embolic protection devices, which have been shown to reduce the gamble for periprocedural myocardial infarction,⁵ were only used in xiv% to 16%.

How should bypass graft failure be treated? If PCI of the bypass graft is performed, then DES (second generation, because beginning generation are no longer available anyway) should be used because they likely reduce the risk of restenosis. Alternatively, the native coronary artery supplying the same territory may be treated and is actually preferred to treating the bypass graft lesion (especially if the bypass graft is occluded), equally it likely provides improve long-term patency.¹² However, such procedures tin oftentimes be complex, requiring expertise in treating chronic total occlusions, bifurcations, tortuous and calcified vessels, and hemodynamic support.^13,14 Redo coronary featherbed graft surgery should be performed rarely because information technology carries high complication risk, especially in patients with patent internal mammary avenue grafts.¹⁵ Prolonged dual antiplatelet therapy^xvi and intensive statin therapy¹⁷ may reduce the take chances of recurrent events. In the hereafter, even more aggressive low-density lipoprotein cholesterol lowering, such every bit administration of proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors could be considered, although these strategies will require further written report.

Minimizing the run a risk for recurrent graft or native coronary artery failure past using DES and ideally using embolic protection devices is something that we can and should practice. We should also optimize antiplatelet and lipid-lowering therapy and care for other cardiac and noncardiac comorbidities (Effigy). Many patients may, however, have boosted conditions (such as frailty, dementia, or avant-garde cardiac or noncardiac disease) that we may but be able to treat by providing pity and support.

Disclosures

Dr Karacsonyi: none.

Dr Brilakis: consulting/speaker honoraria from Abbott Vascular, Asahi, Cardinal Health, Elsevier and GE Healthcare; inquiry support from Boston Scientific and InfraRedx; spouse is employee of Medtronic.

Footnotes

The opinions expressed in this commodity are not necessarily those of the editors or of the American Heart Association.

Correspondence to Emmanouil Due south. Brilakis, Medico, PhD, Minneapolis Heart Establish, 920 E 28th St No. 300, Minneapolis, MN 55407. E-mail [e-mail protected]

References

• ane. Iqbal J, Kwok CS, Kontopantelis E, de Belder MA, Ludman PF, Big A, Butler R, Gamal A, Kinnaird T, Zaman A, Mamas MA; British Cardiovascular Intervention Society (BCIS); National Institute of Cardiovascular Consequence Research (NICOR). Pick of stent for percutaneous coronary intervention of saphenous vein grafts. Circ Cardiovasc Interv . 2017; 10:e004457. doi: ten.1161/CIRCINTERVENTIONS.116.004457.LinkGoogle Scholar
• 2. Brilakis ES, Lee G, Mehilli J, Marmagkiolis K, Rodes-Cabau J, Sachdeva R, Kotsia A, Christopoulos G, Rangan BV, Mohammed A, Banerjee S. Saphenous vein graft interventions. Curr Treat Options Cardiovasc Med . 2014; 16:301. doi: 10.1007/s11936-014-0301-x.CrossrefMedlineGoogle Scholar
• 3. Brilakis ES, Rao SV, Banerjee S, Goldman S, Shunk KA, Holmes DR, Honeycutt E, Roe MT. Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary avenue featherbed grafting patients: a report from the National Cardiovascular Information Registry. JACC Cardiovasc Interv . 2011; 4:844–850. doi: x.1016/j.jcin.2011.03.018.CrossrefMedlineGoogle Scholar
• four. Brilakis ES, O'Donnell CI, Penny W, Armstrong EJ, Tsai T, Maddox TM, Plomondon ME, Banerjee S, Rao SV, Garcia Southward, Nallamothu B, Shunk KA, Mavromatis Thou, Grunwald GK, Bhatt DL. Percutaneous coronary intervention in native coronary arteries versus bypass grafts in patients with prior coronary avenue bypass graft surgery: insights from the veterans affairs clinical assessment, reporting, and tracking plan. JACC Cardiovasc Interv . 2016; 9:884–893. doi: 10.1016/j.jcin.2016.01.034.CrossrefMedlineGoogle Scholar
• five. Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, Kaya U, Popma JJ, Ho KK, Kuntz RE; Saphenous Vein Graft Angioplasty Complimentary of Emboli Randomized (SAFER) Trial Investigators. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Apportionment . 2002; 105:1285–1290. doi: 10.1161/01.CIR.0000012783.63093.0C.CrossrefMedlineGoogle Scholar
• 6. Mosleh West, Gandhi Southward, Elsiddig Thousand, Schwalm JD, Farkouh ME. Comparison of drug-eluting stents with bare-metal stents for PCI of saphenous vein graft lesions: systematic review and meta-analysis. J Invasive Cardiol . 2016; 28:E139–E169.MedlineGoogle Scholar
• 7. Abdel-Karim AR, Da Silva Chiliad, Lichtenwalter C, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Makke L, Jeroudi OM, Raghunathan D, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES. Prevalence and outcomes of intermediate saphenous vein graft lesions: findings from the stenting of saphenous vein grafts randomized-controlled trial. Int J Cardiol . 2013; 168:2468–2473. doi: 10.1016/j.ijcard.2013.03.006.CrossrefMedlineGoogle Scholar
• eight. Rodes-Cabau J, Jolly SS, Cairns J, Mansour Southward, Fifty'Allier PL, Teefy PJ, Graham JJ, Le May MR, Cantor WJ, Wood D, Balasubramanian One thousand, DeLarochelliere R, Dzavik Five; Investigators VI. Sealing intermediate nonobstructive coronary saphenous vein graft lesions with drug-eluting stents as a new arroyo to reducing cardiac events: a randomized controlled trial. Circ Cardiovasc Interv . 2016; nine:e004336. doi: 10.1161/CIRCINTERVENTIONS.116.004336.LinkGoogle Scholar
• 9. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai Grand, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Rock GW. Safety and efficacy of drug-eluting and blank metal stents: comprehensive meta-analysis of randomized trials and observational studies. Apportionment . 2009; 119:3198–3206. doi: 10.1161/CIRCULATIONAHA.108.826479.LinkGoogle Scholar
• 10. Michael TT, Alomar M, Papayannis A, Mogabgab O, Patel VG, Rangan BV, Luna One thousand, Hastings JL, Grodin J, Abdullah S, Banerjee S, Brilakis ES. A randomized comparison of the transradial and transfemoral approaches for coronary artery bypass graft angiography and intervention: the RADIAL-CABG Trial (RADIAL Versus Femoral Access for Coronary Artery Bypass Graft Angiography and Intervention). JACC Cardiovasc Interv . 2013; 6:1138–1144. doi: ten.1016/j.jcin.2013.08.004.CrossrefMedlineGoogle Scholar
• 11. Roffi M, Mukherjee D, Chew DP, Bhatt DL, Cho L, Robbins MA, Ziada KM, Brennan DM, Ellis SG, Topol EJ. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation . 2002; 106:3063–3067.LinkGoogle Scholar
• 12. Abdel-Karim AR, Banerjee S, Brilakis ES. Percutaneous intervention of acutely occluded saphenous vein grafts: contemporary techniques and outcomes. J Invasive Cardiol . 2010; 22:253–257.MedlineGoogle Scholar
• 13. Brilakis ES, Banerjee Southward, Lombardi WL. Retrograde recanalization of native coronary artery chronic occlusions via acutely occluded vein grafts. Catheter Cardiovasc Interv . 2010; 75:109–113. doi: 10.1002/ccd.22196.MedlineGoogle Scholar
• 14. Kirtane AJ, Doshi D, Leon MB, Lasala JM, Ohman EM, O'Neill WW, Shroff A, Cohen MG, Palacios IF, Beohar N, Uriel Due north, Kapur NK, Karmpaliotis D, Lombardi W, Dangas GD, Parikh MA, Stone GW, Moses JW. Handling of higher-risk patients with an indication for revascularization: evolution inside the field of contemporary percutaneous coronary intervention. Circulation . 2016; 134:422–431. doi: x.1161/CIRCULATIONAHA.116.022061.LinkGoogle Scholar
• 15. Morrison DA, Sethi G, Sacks J, Henderson West, Grover F, Sedlis S, Esposito R, Ramanathan Thousand, Weiman D, Saucedo J, Antakli T, Paramesh Five, Pett S, Vernon S, Birjiniuk 5, Welt F, Krucoff Thou, Wolfe West, Lucke JC, Mediratta Southward, Booth D, Barbiere C, Lewis D; Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and take chances factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Diplomacy Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (Awesome). J Am Coll Cardiol . 2001; 38:143–149. doi: x.1016/S0735-1097(01)01366-3.CrossrefMedlineGoogle Scholar
• 16. Sachdeva A, Bavisetty Due south, Beckham G, Shen AY, Aharonian 5, Mansukhani P, Rock GW, Leon M, Moses J, Moore N, Hyett R, Contreras R, Brar SS. Discontinuation of long-term clopidogrel therapy is associated with death and myocardial infarction later saphenous vein graft percutaneous coronary intervention. J Am Coll Cardiol . 2012; 60:2357–2363. doi: 10.1016/j.jacc.2012.09.014.CrossrefMedlineGoogle Scholar
• 17. Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Potato SA, Morrow DA, Sabatine MS, Banerjee South, Blazing MA, Califf RM, Braunwald E. Outcomes of patients with astute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Am J Cardiol . 2008; 102:552–558. doi: x.1016/j.amjcard.2008.04.024.CrossrefMedlineGoogle Scholar

floresdialt1936.blogspot.com

Source: https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.117.005212

Share this post